LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants

Westendorf, K; Zentelis, S; Wang, LS; Foster, D; Vaillancourt, P; Wiggin, M; Lovett, E; van der Lee, R; Hendle, J; Pustilnik, A; Sauder, JM; Kraft, L; Hwang, Y; Siegel, RW; Chen, JB; Heinz, BA; Higgs, RE; Kallewaard, NL; Jepson, K; Goya, R; Smith, MA; Collins, DW; Pellacani, D; Xiang, P; de Puyraimond, V; Ricicova, M; Devorkin, L; Pritchard, C; O'Neill, A; Dalal, K; Panwar, P; Dhupar, H; Garces, FA; Cohen, CA; Dye, JM; Huie, KE; Badger, CV; Kobasa, D; Audet, J; Freitas, JJ; Hassanali, S; Hughes, I; Munoz, L; Palma, HC; Ramamurthy, B; Cross, RW; Geisbert, TW; Menachery, V; Lokugamage, K; Borisevich, V; Lanz, I; Anderson, L; Sipahimalani, P; Corbett, KS; Yang, ES; Zhang, Y; Shi, W; Zhou, TQ; Choe, M; Misasi, J; Kwong, PD; Sullivan, NJ; Graham, BS; Fernandez, TL; Hansen, CL; Falconer, E; Mascola, JR; Jones, BE; Barnhart, BC

Barnhart, BC (通讯作者),AbCellera Biol Inc, Vancouver, BC V5Y 0A1, Canada.;Jones, BE (通讯作者),Eli Lilly & Co, Lilly Biotechnol Ctr, San Diego, CA 92121 USA.

CELL REPORTS, 2022; 39 (7):

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-neutralizing monoclonal antibodies (mAbs) can reduce the risk of hospitalization from cor......

Full Text Link